Genmab A (GMAB) Gross Profit (2018 - 2026)

Genmab A (GMAB) has reported Gross Profit for 8 consecutive years, with $1.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit fell 30.5% year-over-year to $1.1 billion; the trailing twelve-month figure through Jun 2026 stood at $5.9 billion (up 5.39% YoY), and the FY2025 full-year result was $3.5 billion, up 16.92% from the prior year.
• Gross Profit rose to $1.1 billion in Q2 2026 per GMAB's latest filing, from $831.0 million in the prior quarter.
• Across five years, Gross Profit topped out at $4.6 billion in Q3 2023 and bottomed at -$9.4 billion in Q4 2023.
• Historically, Gross Profit has averaged $583.2 million across 4 years, with a median of $1.2 billion in 2024.
• The sharpest annual moves came in 2024 and 2026: Gross Profit tumbled 54.72% in 2024, then rose 23.48% in 2026.
• Over 4 years, Gross Profit stood at -$9.4 billion in 2023, then surged by 122.28% to $2.1 billion in 2024, then advanced by 19.12% to $2.5 billion in 2025, then sank by 57.25% to $1.1 billion in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $1.1 billion, $831.0 million, and $2.5 billion for Q2 2026, Q1 2026, and Q3 2025 respectively.